Remegen ：Telitacicept receives approval for dual indications.

On June 8, the NMPA official website showed that Remegen’s Telitacicept (brand name: Tai’ai®) has been approved for two new indications: 1) for the treatment of adult patients with primary immunoglobulin A (IgA) nephropathy at risk of disease progression to significantly reduce proteinuria levels (Acceptance No.: CXSS2500112); and 2) for the treatment of Sjögren’s syndrome (Acceptance No.: CXSS2500090).

Telitacicept (RC18) is a BLyS/APRIL dual-target fusion protein innovative drug independently developed by Remegen. By simultaneously inhibiting the overexpression of two cytokines—B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL)—it acts through a “dual-pronged” approach to block the abnormal differentiation and maturation of B cells, thereby treating various B-cell-mediated immune diseases.

Buy Telitacicept online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.